CKD Tied to Depression Risk, More So in Young Patients
Patients with chronic kidney disease (CKD) showed a 2.6-fold higher risk for depression requiring antidepressant treatment than those without CKD. The greatest risk was observed in those younger than 60 years.
METHODOLOGY:
Depression is one of the most common psychiatric conditions in patients with CKD. However, evidence from large population-based studies on whether CKD increases the risk for depression requiring treatment is limited.
Researchers conducted a retrospective cohort study using data from primary care practices in Germany between 2005 and 2022 to examine the association between CKD and the risk of developing depression requiring treatment.
They included 165,787 patients (mean age, 71.6 years; 48.3% women) with CKD and matched them to control individuals without CKD using propensity score matching.
Patients with schizophrenia, mood disorders, and neurotic disorders documented within 12 months prior to or on the date of the CKD diagnosis were excluded.
The outcome was the diagnosis of depression within up to 10 years following the diagnosis of CKD; antidepressant prescriptions were evaluated in participants with a diagnosis of depression.
TAKEAWAY:
The 10-year cumulative incidence of depression and depression followed by an antidepressant prescription was significantly higher in patients with CKD than in those without ( P < .001 for both).
< .001 for both). Patients with CKD had a 2.6-fold higher risk for depression requiring antidepressant treatment than those without CKD (hazard ratio [HR], 2.63; P < .001), with the strongest effect found in those younger than 60 years (HR, 6.03; P < .001).
< .001), with the strongest effect found in those younger than 60 years (HR, 6.03; < .001). Mirtazapine was the most commonly prescribed antidepressant in both CKD and non-CKD groups, followed by citalopram, opipramol, amitriptyline, and escitalopram.
IN PRACTICE:
"Our findings argue against strict screening protocols for the detection of depression in all patients with CKD. Though, some awareness should be raised for younger patients, given that depression risk was highest in this subgroup," the authors wrote.
SOURCE:
This study was led by Andreas Kommer, University Medical Center of the Johannes Gutenberg University, Mainz, Germany. It was published online on June 12, 2025, in Clinical Kidney Journal .
LIMITATIONS:
This study relied on diagnostic codes, which could have led to miscoding or undercoding. The database lacked information on how depression was diagnosed. Additionally, laboratory values were not available for every patient, making it impossible to track the progression of CKD and the initiation of renal replacement therapy.
DISCLOSURES:
This study did not receive any grant or funding. Two authors reported receiving support through the Clinician Scientist Fellowship, Else Kröner Research College . One author reported being an employee of IQVIA.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
34 minutes ago
- Medscape
CMR in MINOCA Linked to Improved Diagnosis and Management
TOPLINE: In a prospective study of over 300 patients with myocardial infarction with nonobstructive coronary arteries (MINOCA), cardiovascular magnetic resonance (CMR) was associated with meaningful changes in clinical diagnosis and/or management in 63% of patients and a similar increase in diagnostic certainty. METHODOLOGY: Previous CMR studies in MINOCA have focused on radiologic yield — a limited metric that does not reflect real‐world clinical utility. Prospective data on patient care are lacking. This prospective study conducted in Australia and the UK assessed the impact of CMR on diagnosis and management in 320 patients with MINOCA (mean age, 55.6 years; 52% men) recruited between January 2019 and July 2023. Patients were included if they had a hospital admission with acute features consistent with the Fourth Universal Definition of Myocardial Infarction, no obstructive coronary artery disease on angiography, and a clinician assessment indicating acute myocardial infarction as the most likely presentation. The treating cardiologists completed a questionnaire before and after CMR to record their working diagnosis, rate diagnostic certainty on a 1-10 scale (10 = most certain), and specify intended management, including medications and follow-up testing. The primary endpoint was a composite of change in clinical diagnosis or management after CMR. TAKEAWAY: CMR was associated with a change in diagnosis or management in 63% of patients (P < .001), with diagnosis revised in 38% and management changed in 50%. Diagnostic certainty increased significantly from a median score of 6-8 after CMR (P < .001), and diagnostic confidence numerically increased in 63% of patients. The absence of coronary atheroma, a pre-CMR diagnostic certainty score ≤ 5, and early CMR (performed within 14 days of hospital presentation) independently predicted a change in diagnosis or management, with 80% of patients with all three predictors vs 40% of those with none meeting the primary outcome. Of 172 patients initially prescribed dual antiplatelet therapy, 66 (38%) had it deprescribed following CMR, yielding a number needed to test of 3. IN PRACTICE: 'Integration of CMR into diagnostic imaging pathways may be reasonable to augment clinical diagnosis and management; however, further cost-effectiveness analyses are now warranted,' the study authors wrote. SOURCE: This study was led by Adil Rajwani, PhD, of the Royal Perth Hospital, Perth, Australia. It was published online on June 13, 2025, in Heart. LIMITATIONS: The study was limited by the impracticality of conducting a bias-free randomized trial of CMR vs no CMR. It was also limited by the assessment of CMR's impact only immediately after imaging, potentially missing later clinical insights. Medication protocols were not standardized, and the limited use of additional diagnostics such as optical coherence tomography may have influenced the findings. DISCLOSURES: This study was funded by a grant from the Royal Perth Hospital Medical Research Foundation in Australia. The authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
2 hours ago
- Yahoo
Inside The Disney-Inspired Office Campus with 13,000 Employees
Epic is the leading provider of electronic medical records in the U.S.-- but its headquarters looks nothing like a typical tech Wisconsin HQ features treehouses, yellow brick roads, and even air-tagged sheep. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
GPs can prescribe weight loss jabs on the NHS from today - but strict eligibility criteria in place
GPs will be able to prescribe weight loss jabs on the NHS from today. About 220,000 people with the "greatest need" are set to receive Mounjaro - with strict criteria for the first year of the rollout. Initially, only those with a body mass index of over 40 who have at least four other health problems linked to obesity will be eligible. Some doctors have raised concerns about the additional workload this new programme will bring, while pharmacists fear it could lead to supply shortages. While an estimated 1.5 million people are now taking weight loss drugs across the UK, they could previously only be accessed through specialist services or private prescriptions. Dr Claire Fuller from NHS England said: "We urgently need to address rising levels of obesity and prioritise support for those who are experiencing severe ill health - and greater access to weight loss drugs will make a significant difference to the lives of those people." She added: "While not everyone will be eligible for weight loss drugs, it's important that anyone who is worried about the impact of their weight on their health discusses the range of NHS support available with their healthcare professional." The chairwoman of the Royal College of GPs welcomed NHS England's decision to pursue a phased rollout, and said current workloads must be factored in to ensure the jabs can be prescribed safely. Professor Kamila Hawthorne went on to say: "While weight loss medications have a lot of potential benefits for patients who are struggling to lose weight and who meet all the clinical criteria for a prescription, they mustn't be seen as a 'silver bullet' to aid weight loss. "We also need to see a focus on prevention, stopping people becoming overweight in the first place so they don't require a medical intervention later." Read more from Sky News:UK and NATO allies to boost defence spending Her remarks were echoed by the National Pharmacy Association's chairman Olivier Picard, who says "prescribing these medications alone misses the point". He argued that they need to be part of a comprehensive strategy that includes lifestyle coaching, exercise and nutritional guidance - but many GPs currently "lack the bandwidth" to provide this support. "As a result, we could end up in a situation where patients are prescribed the medication, lose weight, and then experience rebound weight gain once the course ends - simply because the foundational lifestyle changes weren't addressed," Mr Picard added. Estimates suggest about 29% of the adult population is obese. Health Secretary Wes Streeting says the government "is determined to bring revolutionary modern treatments to everyone who needs them, not just those who can afford to pay".
